Bardoxolone methyl: drug development for diabetic kidney disease

Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies....

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Hironori, Yamawaki, Kengo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497696/
https://www.ncbi.nlm.nih.gov/pubmed/32594372
http://dx.doi.org/10.1007/s10157-020-01917-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497696/
https://www.ncbi.nlm.nih.gov/pubmed/32594372
http://dx.doi.org/10.1007/s10157-020-01917-5

Ejemplares similares